Log In
Print this Print this

Biomarker risk assignment algorithm

  Manage Alerts
Collapse Summary General Information
Company Zinfandel Pharmaceuticals Inc.
DescriptionGenetics-based biomarker risk assignment algorithm based on APOE and TOMM40 genotypes and age
Molecular Target Apolipoprotein E (APOE) ; Translocase of outer mitochondrial membrane 40 homolog (TOMM40) (TOM40)
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentPhase III
Standard IndicationNeurology, Diagnostic
Indication DetailsPredict onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD)
Regulatory Designation
PartnerTakeda Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today